Methotrexate increases skeletal muscle GLUT4 expression and improves metabolic control in experimental diabetes

Journal of Nutrition and Metabolism

Volumn 2012, Issue , 2012, Pages

  Russo, Giuseppina T ^a   Minutoli, Letteria ^a   Bitto, Alessandra ^a   Altavilla, Domenica ^a   Alessi, Eugenio ^a   Giandalia, Annalisa ^a   Romeo, Elisabetta L ^a   Stagno, Maria Francesca ^a   Squadrito, Francesco ^a   Cucinotta, Domenico ^a   Selhub, Jacob ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 84873848622     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2012/132056     Document Type: Article

References (51)

1. Hayashi T., Wojtaszewski J. F. P., Goodyear L. J., Exercise regulation of glucose transport in skeletal muscle. American Journal of Physiology 1997 273 6 E1039 E1051 2-s2.0-0031417390
2. Kennedy J. W., Hirshman M. F., Gervino E. V., Ocel J. V., Forse R. A., Hoenig S. J., Aronson D., Goodyear L. J., Horton E. S., Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes 1999 48 5 1192 1197 2-s2.0-0032954067 10.2337/diabetes.48.5.1192 (Pubitemid 29226370)
3. Lauritzen H. P., Schertzer J. D., Measuring GLUT4 translocation in mature muscle fibers. American Journal of Physiology 2010 299 2 E169 E179 2-s2.0-77954921616 10.1152/ajpendo.00066.2010
4. Lauritzen H. P., Galbo H., Toyoda T., Goodyear L. J., Kinetics of contraction-induced GLUT4 translocation in skeletal muscle fibers from living mice. Diabetes 2010 59 9 2134 2144 2-s2.0-77956367748 10.2337/db10-0233
5. Corton J. M., Gillespie J. G., Hardie D. G., Role of the AMP-activated protein kinase in the cellular stress response. Current Biology 1994 4 4 315 324 2-s2.0-0028406897 10.1016/S0960-9822(00)00070-1 (Pubitemid 2069614)
6. Winder W. W., Hardie D. G., Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. American Journal of Physiology 1996 270 2 E299 E304 2-s2.0-0029978799
7. Hutber C. A., Hardie D. G., Winder W. W., Electrical stimulation inactivates muscle acetyl-CoA carboxylase and increases AMP-activated protein kinase. American Journal of Physiology 1997 272 2 E262 E266 2-s2.0-0030901556
8. Kudo N., Barr A. J., Barr R. L., Desai S., Lopaschuk G. D., High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. The Journal of Biological Chemistry 1995 270 17513 17520 2-s2.0-0029093341 10.1074/jbc.270.29.17513
9. Salt I. P., Johnson G., Ashcroft S. J. H., Hardie D. G., AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic β cells, and may regulate insulin release. Biochemical Journal 1998 335 3 533 539 2-s2.0-0032213768 (Pubitemid 28515405)
10. Tsao T.-S., Li J., Chang K. S., Stenbit A. E., Galuska D., Anderson J. E., Zierath J. R., Mccarter R. J., Charron M. J., Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity. FASEB Journal 2001 15 6 958 969 2-s2.0-0035074525 10.1096/fj.00-0381 (Pubitemid 32290783)
11. Zisman A., Peroni O. D., Abel E. D., Michael M. D., Mauvais-Jarvis F., Lowell B. B., Wojtaszewski J. F. P., Hirshman M. F., Virkamaki A., Goodyear L. J., Kahn C. R., Kahn B. B., Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nature Medicine 2000 6 8 924 928 2-s2.0-0033834248 10.1038/78693 (Pubitemid 30644753)
12. Koranyi L. I., Bourey R. E., Vuorinen-Markkola H., Koivisto V. A., Mueckler M., Permutt M. A., Yki-Jarvinen H., Level of skeletal muscle glucose transporter protein correlates with insulin-stimulated whole body glucose disposal in man. Diabetologia 1991 34 10 763 765 2-s2.0-0025949939
13. Corton J. M., Gillespie J. G., Hawley S. A., Hardie D. G., 5-aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? European Journal of Biochemistry 1995 229 2 558 565 2-s2.0-0028988001
14. Merrill G. F., Kurth E. J., Hardie D. G., Winder W. W., AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. American Journal of Physiology 1997 273 6 E1107 E1112 2-s2.0-0031425839
15. Hall J. L., Sexton W. L., Stanley W. C., Exercise training attenuates the reduction in myocardial GLUT-4 in diabetic rats. Journal of Applied Physiology 1995 78 1 76 81 2-s2.0-0028896672
16. Ploug T., Stallknecht B. M., Pedersen O., Kahn B. B., Ohkuwa T., Vinten J., Galbo H., Effect of endurance training on glucose transport capacity and glucose transporter expression in rat skeletal muscle. American Journal of Physiology 1990 259 6 E778 E786 2-s2.0-0025614980
17. Holmes B. F., Kurth-Kraczek E. J., Winder W. W., Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. Journal of Applied Physiology 1999 87 5 1990 1995 2-s2.0-0032704115
18. Winder W. W., Holmes B. F., Rubink D. S., Jensen E. B., Chen M., Holloszy J. O., Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. Journal of Applied Physiology 2000 88 6 2219 2226 2-s2.0-0033949848 (Pubitemid 30453931)
19. Buhl E. S., Jessen N., Schmitz O., Pedersen S. B., Pedersen O., Holman G. D., Lund S., Chronic treatment with 5-aminoimidazole-4-carboxamide-1- β -D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 2001 50 1 12 17 2-s2.0-0035155821 (Pubitemid 32047974)
20. Weinblatt M. E., Maier A. L., Fraser P. A., Coblyn J. S., Long term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. Journal of Rheumatology 1998 25 2 238 242 2-s2.0-0031887318 (Pubitemid 28088249)
21. Feagan B. G., Fedorak R. N., Irvine E. J., A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's study group investigators. The New England Journal of Medicine 2000 342 22 1627 1632 (Pubitemid 30341531)
22. Genestier L., Paillot R., Quemeneur L., Izeradjene K., Revillard J. P., Mechanisms of action of methotrexate. Immunopharmacology 2000 47 2-3 247 257 2-s2.0-0034043034 10.1016/S0162-3109(00)00189-2 (Pubitemid 30394541)
23. Baggott J. E., Vaughn W. H., Hudson B. B., Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochemical Journal 1986 236 1 193 200 2-s2.0-0022637441 (Pubitemid 16095531)
24. Hornung N., Stengaard-Pedersen K., Ehrnrooth E., Ellingsen T., Poulsen J. H., The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells. Clinical and Experimental Rheumatology 2000 18 6 691 698 2-s2.0-0033652159
25. Morabito L., Montesinos M. C., Schreibman D. M., Balter L., Thompson L. F., Resta R., Carlin G., Huie M. A., Cronstein B. N., Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires Ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. The Journal of Clinical Investigation 1998 101 2 295 300 2-s2.0-0032518281 (Pubitemid 28067325)
26. Cronstein B. N., Naime D., Ostad E., The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocytes accumulation in an in vivo model of inflammation. The Journal of Clinical Investigation 1993 92 6 2675 2682 2-s2.0-0027139914 (Pubitemid 24006532)
27. Montesinos M. C., Takedachi M., Thompson L. F., Wilder T. F., Fernández P., Cronstein B. N., The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-5′-nucleotidase gene-deficient mice. Arthritis and Rheumatism 2007 56 5 1440 1445 2-s2.0-34248524004 10.1002/art.22643 (Pubitemid 46764071)
28. Reiss A. B., Carsons S. E., Anwar K., Rao S., Edelman S. D., Zhang H., Fernandez P., Cronstein B. N., Chan E. S. L., Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis and Rheumatism 2008 58 12 3675 3683 2-s2.0-57349141486 10.1002/art.24040
29. Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
30. Buhl E. S., Jessen N., Pold R., Ledet T., Flyvbjerg A., Pedersen S. B., Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002 51 7 2199 2206 2-s2.0-0036307179 (Pubitemid 34729025)
31. Tian H., Cronstein B. N., Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007 65 3 168 173 2-s2.0-38449094689 (Pubitemid 351412127)
32. Towler M. C., Hardie D. G., AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research 2007 100 3 328 341 2-s2.0-33847080728 10.1161/01.RES.0000256090.42690.05
33. Russell R. R. III, Bergeron R., Shulman G. I., Young L. H., Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. American Journal of Physiology 1999 277 2 H643 H649 2-s2.0-0032881635 (Pubitemid 29415978)
34. Kurth-Kraczek E. J., Hirshman M. F., Goodyear L. J., Winder W. W., 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999 48 8 1667 1671 2-s2.0-0032765396 10.2337/diabetes.48.8.1667 (Pubitemid 29356879)
35. Bergeron R., Russell R. R. III, Young L. H., Ren J. M., Marcucci M., Lee A., Shulman G. I., Effect of AMPK activation on muscle glucose metabolism in conscious rats. American Journal of Physiology 1999 276 5 E938 E944 2-s2.0-0032966874 (Pubitemid 29249614)
36. Gibbs M. E., Stock J. L., McCoid S. C., Stukenbrok H. A., Pessin J. E., Stevenson R. W., Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). The Journal of Clinical Investigation 1995 95 4 1512 1518 2-s2.0-0028942658
37. Halseth A. E., Ensor N. J., White T. A., Ross S. A., Gulve E. A., Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochemical and Biophysical Research Communications 2002 294 4 798 805 2-s2.0-0036289911 10.1016/S0006-291X(02)00557-0 (Pubitemid 34687187)
38. Vincent M. F., Marangos P. J., Gruber H. E., Van den Berghe G., Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991 40 10 1259 1266 2-s2.0-0026063181
39. Babiak R. M., Campello A. P., Carnieri E. G., Oliveira M. B., Methotrexate: pentose cycle and oxidative stress. Cell Biochemistry and Function 1998 16 4 283 293 (Pubitemid 28523763)
40. Donath M. Y., Shoelson S. E., Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology 2011 11 2 98 107 2-s2.0-79151478555 10.1038/nri2925
41. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
42. Westlake S. L., Colebatch A. N., Baird J., Kiely P., Quinn M., Choy E., Ostor A. J. K., Edwards C. J., The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2009 49 2 295 307 2-s2.0-77950441072 10.1093/rheumatology/kep366
43. Majumdar S., Aggarwal B. B., Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phpsphorilation and degradation. The Journal of Immunology 2001 167 2911 2920 (Pubitemid 32768926)
44. Yozai K., Shikata K., Sasaki M., Tone A., Ohga S., Usui H., Okada S., Wada J., Nagase R., Ogawa D., Shikata Y., Makino H., Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. Journal of the American Society of Nephrology 2005 16 11 3326 3338 2-s2.0-33644876409 10.1681/ASN.2004111011 (Pubitemid 46179336)
45. Goldfine A. B., Fonseca V., Shoelson S. E., Therapeutic approaches to target inflammation in type 2 diabetes. Clinical Chemistry 2011 57 2 162 167 2-s2.0-79551470814 10.1373/clinchem.2010.148833
46. Donath M. Y., Shoelson S. E., Type 2 diabetes as an inflammatory disease. Nature Reviews Immunology 2011 11 2 98 107 2-s2.0-79151478555 10.1038/nri2925
47. Goldfine A. B., Fonseca V., Jablonski K. A., The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Annals of Internal Medicine 2010 152 6 346 357 2-s2.0-77950885686
48. Halonen P., Salo M. K., Mäkipernaa A., Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia. Journal of Pediatrics 2001 138 3 428 431 2-s2.0-0035089984 10.1067/mpd.2001. 111273 (Pubitemid 32207152)
49. Halonen P., Salo M. K., Schmiegelow K., Mäkipernaa A., Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatrica 2003 92 1 37 42 2-s2.0-0037284915 (Pubitemid 36255929)
50. Rekedal L. R., Massarotti E., Garg R., Bhatia R., Gleeson T., Lu B., Solomon D. H., Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis and Rheumatism 2010 62 12 3569 3573 2-s2.0-78650050052 10.1002/art.27703
51. Sobel D. O., Henzke A., Abbassi V., Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetologica 2010 47 3 243 250 2-s2.0-77955653658 10.1007/s00592-010-0188-2